



September 23, 2023

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Scrip code: 532531

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
Scrip code: STAR

Dear Madam/ Sir,

**Sub: Press Release**

Please find attached Press Release issued by the Company titled:

**“Strides receives USFDA approval for Icosapent Ethyl Capsules”**

Thanks & Regards,  
For **Strides Pharma Science Limited**,

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

Encl. As above

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

## Strides receives USFDA approval for Icosapent Ethyl Capsules

- *Product marks another successful first cycle approval for the Company*
- *Significant market opportunity with ~USD 1.3Bn sales as per IQVIA*
- *To be introduced into the market immediately in partnership with a leading generic company*

**Bangalore, India, Sep 23, 2023** - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Icosapent Ethyl Capsules 0.5 gram and 1 gram, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Vascepa of Amarin®. The Icosapent Ethyl Capsules has a market size of ~USD 1.3Bn per IQVIA. The product will be manufactured at the Company's facility in Bengaluru.

The Company has 260 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with USFDA, of which 230+ ANDAs have been approved. The Company has set a target to launch ~ 60 new products over three years in the US.

### About Icosapent Ethyl Capsule

Icosapent Ethyl Capsule is a prescription medication used in conjunction with other medicines like statins to reduce the risk of heart attack, stroke and heart issues in those afflicted with cardiovascular disease. The product complements Strides' range of approved soft gelatin capsules.

### About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on "difficult to manufacture" products sold in over 100 countries. Additional information is available at the Company's website at [www.strides.com](http://www.strides.com).

**For further information, please contact:**

**Strides**

**Badree Komandur**

Executive Director – Finance & Group CFO  
+91 80 6784 0747

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,  
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,  
Bengaluru – 560076

**Corporate Communication**

**Pallavi Panchmatia:** +91 80 6784 0193

Email: [pallavi.panchmatia@strides.com](mailto:pallavi.panchmatia@strides.com)

**PR Consultancy**

Fortuna PR

K Srinivas Reddy: +91 90005 27213

[srinivas@fortunapr.com](mailto:srinivas@fortunapr.com)

Boni Mukherjee: +91 96186 82208

[boni@fortunapr.com](mailto:boni@fortunapr.com)